-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, RQRGuvyhy2O8HgUTCozWbDZuoCLMtNdIwPvb3HBfWhQpstAZ3gVtfTWbdIcdoR4N 7tUUGH5QTLAgcixJc+yH0w== 0000950135-04-003392.txt : 20040702 0000950135-04-003392.hdr.sgml : 20040702 20040702104208 ACCESSION NUMBER: 0000950135-04-003392 CONFORMED SUBMISSION TYPE: 425 PUBLIC DOCUMENT COUNT: 3 FILED AS OF DATE: 20040702 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: FISHER SCIENTIFIC INTERNATIONAL INC CENTRAL INDEX KEY: 0000880430 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-PROFESSIONAL & COMMERCIAL EQUIPMENT & SUPPLIES [5040] IRS NUMBER: 020451017 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 425 SEC ACT: 1934 Act SEC FILE NUMBER: 001-10920 FILM NUMBER: 04897638 BUSINESS ADDRESS: STREET 1: LIBERTY LANE CITY: HAMPTON STATE: NH ZIP: 03842 BUSINESS PHONE: 6039265911 MAIL ADDRESS: STREET 1: LIBERTY LANE CITY: LIBEHAMPTON STATE: NH ZIP: 03842 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: FISHER SCIENTIFIC INTERNATIONAL INC CENTRAL INDEX KEY: 0000880430 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-PROFESSIONAL & COMMERCIAL EQUIPMENT & SUPPLIES [5040] IRS NUMBER: 020451017 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 425 BUSINESS ADDRESS: STREET 1: LIBERTY LANE CITY: HAMPTON STATE: NH ZIP: 03842 BUSINESS PHONE: 6039265911 MAIL ADDRESS: STREET 1: LIBERTY LANE CITY: LIBEHAMPTON STATE: NH ZIP: 03842 425 1 b51065fse425.htm FISHER SCIENTIFIC INTERNATIONAL INC. FISHER SCIENTIFIC INTERNATIONAL INC.
 

Filed by Fisher Scientific International Inc.
pursuant to Rule 425 under the Securities Act of 1933
and deemed filed pursuant to Rule 14a-12
under the Securities and Exchange Act of 1934, as amended

Subject Company: Fisher Scientific International Inc.
Commission File No.: 1-10920

This filing relates to a planned merger (the “Merger”) between Fisher Scientific International Inc. (“Fisher”) and Apogent Technologies Inc. (“Apogent”) pursuant to the terms of an Amended and Restated Agreement and Plan of Merger, dated as of March 17, 2004, as amended April 16, 2004 (the “Merger Agreement”), by and among Fisher, Fox Merger Corporation and Apogent. The Merger Agreement is on file with the U.S. Securities and Exchange Commission (the “SEC”) as an exhibit to the Current Report on Form 8-K, as amended, filed by Fisher on April 16, 2004, and is incorporated by reference into this filing.

(FISHER SCIENTIFIC LOGO)   (APOGENT LOGO)

NEWS RELEASE

       
Media Contact
  Investor Contact
 
Gia L. Oei
  Carolyn Miller
603-929-2489
  603-929-2381

Fisher Scientific and Apogent Extend Exchange Offers

HAMPTON and PORTSMOUTH, N.H., July 2, 2004 — Fisher Scientific International Inc. (NYSE: FSH) and Apogent Technologies Inc. (NYSE: AOT) announced today that they are extending the expiration date for the exchange offer and consent solicitation relating to $345 million of Apogent’s Floating Rate Senior Convertible Contingent Debt Securities due 2033 and exchange offer relating to $300 million of Apogent’s 2.25 percent Senior Convertible Contingent Debt Securities due 2021 in connection with the planned merger between Fisher and Apogent. The exchange offers are each being made pursuant to a preliminary prospectus dated May 28, 2004, and related letter of transmittal, which more fully set forth the terms of the exchange offer.

     The exchange offer and consent solicitation relating to the Floating Rate Senior Convertible Contingent Debt Securities and the exchange offer relating to the 2.25 percent Senior Convertible Contingent Debt Securities, both previously scheduled to expire at 5 p.m. Eastern Daylight Time (EDT) on July 1, 2004, will now expire at 5 p.m. EDT on July 16, 2004, unless extended or terminated earlier. As of 5 p.m. EDT on July 1, 2004, $188.720 million aggregate principal amount of the Floating Rate Senior Convertible Contingent Debt Securities had been tendered for exchange. As of 5 p.m. EDT on July 1, 2004, $171.781 million aggregate principal amount of the 2.25 percent Senior Convertible Contingent Debt Securities had been tendered for exchange.

- more -

 

 

Fisher Scientific and Apogent Extend Exchange Offers — 2

     The offers involve the exchange of up to $345 million of Apogent’s Floating Rate Senior Convertible Contingent Debt Securities due 2033 for new Floating Rate Convertible Senior Debentures due 2033, and up to $300 million of Apogent’s 2.25 percent Senior Convertible Contingent Debt Securities due 2021 for new 2.25 percent Convertible Senior Debentures due 2021. Consents to amend the resale registration rights agreement relating to the Floating Rate Senior Convertible Contingent Debt Securities are also being solicited in connection with that exchange offer. Both series of new Convertible Senior Debentures will remain obligations of Apogent after the completion of the proposed merger but will be convertible into Fisher common stock or, at Apogent’s election, the cash value thereof. The exchange offers are subject to various conditions, including completion of the merger, as described in the preliminary prospectuses.

     Neither Fisher nor Apogent will receive any proceeds from the issuance of the new Convertible Senior Debentures in the exchange offers.

     Goldman, Sachs & Co. is acting as dealer manager, Innisfree M&A Incorporated is the information agent, and The Bank of New York is the exchange agent for the exchange offers. Copies of the registration statements, including the preliminary prospectuses, letters of transmittal and other materials related to the exchange offers, as amended, may be obtained at no charge from Innisfree by calling 888-750-5834 or from the Securities and Exchange Commission’s Web site at www.sec.gov. All questions relating to the mechanics of the exchange offers should be directed to Innisfree at 888-750-5834, or Goldman Sachs, at 800-471-7731. The materials related to the exchange offers contain important information that should be read carefully before any decision is made with respect to the exchange offers.

- more -

 

 

Fisher Scientific and Apogent Extend Exchange Offers — 3

     Registration statements relating to the new Convertible Senior Debentures have been filed with the Securities and Exchange Commission but have not yet become effective. These securities may not be sold nor may offers to buy these securities be accepted prior to the time the registration statements become effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

About Fisher Scientific International Inc.
As a world leader in serving science, Fisher Scientific International Inc. (NYSE: FSH) offers more than 600,000 products and services to more than 350,000 customers located in approximately 145 countries. Fisher’s customers include pharmaceutical and biotech companies; colleges and universities; medical-research institutions; hospitals and reference labs; quality-control, process-control and R&D labs in various industries; as well as government and first responders. As a result of its broad product offering, electronic-commerce capabilities and integrated global logistics network, Fisher serves as a one-stop source of products, services and global solutions for its customers. The company primarily serves the scientific-research, clinical-laboratory and safety markets. Additional information about Fisher is available on the company’s Web site at www.fisherscientific.com.

About Apogent Technologies Inc.
Apogent is a diversified worldwide leader in the design, manufacture, and sale of laboratory and life-science products essential for healthcare diagnostics and scientific research. Apogent’s companies are divided into two business segments for financial reporting purposes: Clinical Group and Research Group.

- more -

 

Fisher Scientific and Apogent Extend Exchange Offers — 4

Additional Information About the Merger and Where to Find it
In connection with the proposed merger, Fisher Scientific and Apogent Technologies have relevant materials on file with the SEC, including an effective registration statement on Form S-4 that contains a prospectus and a joint proxy statement. Investors and security holders are urged to read these documents and any other relevant documents filed with the SEC, as well as any amendments or supplements to those documents, because they will contain important information about Fisher, Apogent and the merger. Investors and security holders may obtain these documents (and any other documents filed by Fisher or Apogent with the SEC) free of charge at the SEC’s Web site at www.sec.gov. In addition, the documents filed with the SEC by Fisher may be obtained free of charge by directing such request to: Corporate Secretary, 1 Liberty Lane, Hampton, NH 03842, or from Fisher’s Web site at www.fisherscientific.com. The documents filed with the SEC by Apogent may be obtained free of charge by directing such request to: Director of Investor Relations, 30 Penhallow Street, Portsmouth, NH 03801, or from Apogent’s Web site at www.apogent.com. Investors and security holders are urged to read the joint proxy statement/prospectus and the other relevant materials before making any voting or investment decision with respect to the proposed merger.

Fisher, Apogent and their respective executive officers and directors may be deemed to be participants in the solicitation of proxies from the stockholders of Fisher and Apogent in favor of the merger. Information about the executive officers and directors of Fisher and their ownership of Fisher common stock is set forth in the joint proxy statement/prospectus filed on Form S-4, which was declared effective by the SEC on May 21, 2004. Information about the executive officers and directors of Apogent and their ownership of Apogent common stock is set forth in the proxy statement for Apogent’s 2004 Annual Meeting of Shareholders, which was filed with the SEC on December 23, 2003. Investors and security holders may obtain more detailed information regarding the direct and indirect interests of Fisher, Apogent and their respective executive officers and directors in the merger by reading the joint proxy statement/prospectus regarding the merger.

###

 

 

* * *

FORWARD LOOKING STATEMENTS

This communication contains statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on Fisher’s and Apogent’s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Risks, uncertainties and assumptions include the possibility that (1) the companies may be unable to obtain stockholder or regulatory approvals required for the Merger; (2) problems may arise in successfully integrating the businesses of the two companies; (3) the acquisition may involve unexpected costs; (4) the combined company may be unable to achieve cost-cutting synergies; (5) the businesses may suffer as a result of uncertainty surrounding the acquisition; and (6) the industry may be subject to future regulatory or legislative actions and other risks that are described in SEC reports filed by Fisher and Apogent. Because forward-looking statements involve risks and uncertainties, actual results and events may differ materially from results and events currently expected by Fisher and Apogent. Fisher and Apogent assume no obligation and expressly disclaim any duty to update the information contained herein except as required by law.

ADDITIONAL INFORMATION ABOUT THE MERGER
AND WHERE TO FIND IT

In connection with the proposed Merger, Fisher and Apogent have on file relevant materials with the SEC, including an effective registration statement on Form S-4 that contains a prospectus and a joint proxy statement. Investors and security holders are urged to read these documents and any other relevant documents filed with the SEC, as well as any amendments or supplements to those

 

 

documents, because they will contain important information about Fisher, Apogent and the Merger. Investors and security holders may obtain these documents (and any other documents filed by Fisher or Apogent with the SEC) free of charge at the SEC’s website at www.sec.gov. In addition, the documents filed with the SEC by Fisher may be obtained free of charge by directing such request to: Corporate Secretary, One Liberty Lane, Hampton, NH 03842 or from Fisher’s website at www.fisherscientific.com. The documents filed with the SEC by Apogent may be obtained free of charge by directing such request to: Director of Investor Relations, 30 Penhallow Street, Portsmouth, NH 03801 or from Apogent’s website at www.apogent.com. Investors and security holders are urged to read the joint proxy statement/prospectus and the other relevant materials before making any voting or investment decision with respect to the proposed Merger.

Fisher, Apogent and their respective executive officers and directors may be deemed to be participants in the solicitation of proxies from the stockholders of Fisher and Apogent in favor of the acquisition. Information about the executive officers and directors of Fisher and their ownership of Fisher common stock is set forth in the joint proxy statement/prospectus filed on Form S-4 which was declared effective by the SEC on May 21, 2004. Information about the executive officers and directors of Apogent and their ownership of Apogent common stock is set forth in the proxy statement for Apogent’s 2004 Annual Meeting of Shareholders, which was filed with the SEC on December 23, 2003. Investors and security holders may obtain more detailed information regarding the direct and indirect interests of Fisher, Apogent and their respective executive officers and directors in the Merger by reading the joint proxy statement/prospectus regarding the Merger.

 

GRAPHIC 2 b51065fsb5106500.gif GRAPHIC begin 644 b51065fsb5106500.gif M1TE&.#EA/P%'`/<````````(A``(C``0A``0C``8C``8E``AC``AE``IE``I MG``QE``QG`@```@`"`@("`@QE`@QG!`("!`($!`0$!`YG!@0$!@0&!@8$!@8 M&!@YG!@YI1A"G!A"I2$8&"$8(2$A(2%"I2%*I2DA(2DA*2DI*2E*I2E2I3$I M*3$I,3$Q,3%2I3%2K3DQ,3DQ.3DY.3E2K3E:K4(Y.4(Y0D)"0D):K4)CK4)C MM4I"0DI"2DI*2DICM4IKM5)*2E)*4E)24E)KM5)SM5I24EI:6EISM5ISO6-: M6F-C8V-[O6MC8VMC:VMK:VMSWM[>WN,QGN4QH1[>X1[A(2$A(24SH2[][6UM[6WM[>WM[>[][GY][G[^?G MY^?G[^?O]^_GY^_G[^_O[^_O]^_W]_?O]_?W]_?W__?_]_?____W]_______ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M____________________________________________________________ M_____________________RP`````/P%'```(_@`_:?K$R9-`@@8'%CRX4&%" MA`P?-H3H,*+%BA@I:IS(4:+'BQL_9NP(DN1(D2%+HC29\J3*ERYCMIS)LN9* MB)P^&@W[527/3E"G/OU)52?3MD@5"8)3!LD.'CMV2"DC2-#`HVV)\EPJ..W3 MMX.;!D;L5G%BP8TA!SX#5RQ48G_DV!D/M`@@0+T*-?D+[]^02X$]CP`[AU=Y_:\^O?S[^_ M__\`'N6=93A]IY91A:R0VWGNL:=>@P^^AQL"GPB2::,1!A%YT)P%FKHH?G-2=E!-\)U M!9A*NGB>;@4,8*FEY;$8Z9(%<&`AG8B&*NJHRQ'VTX!P?7+%BG[RN1L2_EW0 MAU0B8&`!@6X,EJG>`1H(B!R0I`8K;*&BF5@BD*N*R>1Y,P:Q!U)%'94(%AK, MN&R8!WBJDXD]#>OMMU7*::R!KB7+I'OFE7$)8#G)F9.&<%2K:Y,A?`H1N/CF M"Z*B9]WW22*L;IJ>C$W\)>>6Q7T"!WSG[KJ"O83J*_'$_)GZUG$$70)?F!$> M$$$A@K)9'0_F<>Q>`6IX1O'*+%NG96:?U)"GK@4\;)%1.\000PTZ\[QSST#' M8`,0(30\\`$*9=CRTDP[-^")B9DQ0*L%-`&Q43#PIO76O.7:Z@$F"#JB-]ME&(6)V&E],"1W::--AI25I1/'#_@]'>$%(=I9\L38B($82"5*" MF_WW499L,03?5N0QR-M?5,GO9K!Y4D'#\'$!GE$QE+P>>Z277GK'9:970(52 M*F<%``_$WH#LL0-`@5%NP-X``(=/1P'L`.A0Y1(``"`!!11(\```*C1R72.P M+V]WAY8\`<#B1D4/0.5&-?)``Q0\(`$`6V2A?;A.!3F@%*(W6+6:065][?P0 M)K!&P`V:%_)P2&WQ0`8`#*``08`[V(W/$M3Q```E\`,J_0```/S=`R@0P0?( M+3K0$Q\`IA>@ZL7N`80[B@&W=Y0?_`^`Q>O#ZS1H.8M%BQ.04M8!8K`_8*V@ M??2;5P&D\(DRQ/!D_JQ+U5'\%\#E%>^(#S!*((X0A2@<`8'3`8$%,D"!!O:H M#Q"DH@[RX`8I`O`!5+".))CXA"-@#T!TR"((D7*$)3B1#TU<=2S0BE--! M!"V/$H@L2F"7S!G!`JTP'5DV`IC_N1QH&1STO!*6O9!!:\LWA(V.44*#$$3Z"P>"$IYE$;H()T@_D@# M4H9PQ"7TLGA18,X2)+#`)?0N#WT(!"(6D10K_.Z5-`@$4J!W1#?T[Z%'-((H MX[D]3=#@B!3`7O$$6+P79.^(6_C$/04XOA)\(@FO3,H6,%J\B`;(A4)9R!X( M@*0#V$!L/;G$P)25R(Z)0$UK^"%Z9OA)Y1`Q`P^HG"4T,55-NJ$!*(1B[BBX MO/]9```F-8H"`:B"#!"T@D@A9R?%1\7@'66@5#P"!:9X/>:D,8"_`\$/W"#* M3Y8@BQ:@H%D!H,_N91$`>3"*)3(`00O$CJL`".$G:-#)*'A`L&V%8A8%2($> M9.^+8OC$$58901I\P@HG!$`K_PK`P"Z0L``J_E91B#`SCAU@74G;B28@T+#< M%,"WN`DN<'\+LFZ9($_U6Q?_)!G`=F8@L+?#'589"T4J0I4,B!!#\:1G%"]^ MT78!W*!1"*%&&:1A"8(%0$`_@=[6AH]YSGG!=-U;/!U(=K(GE``(7F!=QH80 M>@!L0!V,H@*"3G$+7U#!')-H%!T(]KTG#&=*/P&[L4(5`*:E\!U M*#P*#2:Y7^M^];[[$=>-8K@K)#15+9J(P)+.$NM0.! M:P3I0`>).N>!9V4I_@`L^@DL1O`'KOD$"([(!,.B,+%YR"(%)!M>[CEX@3\@ MA!7.ZLE/!,(+)Z2`&P*Q.#6&%A%]`$$$A4"(OZE2@:IMLYZM*&VR#E"=$WV"3#[%SS8`1U$@:_LI*)+ MC?(`#$!UG8O=L"4,%XG#]H&]9WU`83&(7@"`CZ1&`3$5-0EI>GX"P!Y`+'NY MK()E0WD(GH7#KX5&Z`JD3\+#E%CG15H@$(A:Z\:,LF;I&P>+Q_A98 M.SYVMY.<_H"Q);!.`+_VB+LF87LST("^1B<2=)!O>/7Y`P,3T#DN%W<+,/O* MN5)1`@WN)`J.HF`JG/54$<`0UO-4I] MPU1OYSKYS5BC4-X"EN_0TRKSB85'J`#%'9(FO+0L2&KB]\`/_N]'$ZUMJ@YD M3IUD:.<^W;HK)Q)]^,+F=ST03OK=*$5\0L(S_F#L!YRA$U(6"/#9*]@&0,<2 MC_T?4OHPW0>$5I7]/@H=M8#"(0(X;,\`QAT>.9+ MV/,%;I!0O4-9H<=TG>191I$'[<=7I41OJ4=%#HAU2I2%6]B%\.4?IJ(^_&=\ M3/4=,6,>\_,>AGB(_@7P=@CW"5R`0XIT!3"X@,S'9.0U0025!G3P9P_@95X4 MA-G7-K[T`F0P6KL#`"-@%#/GA,^!")L5/E#5@P!@6EF!5OP5Z5H9G\F@''43IRV"*WX`'RG85"U?'+6@%<'@;-(1;4XI M14M\0%DA68O$Q(#7)V>J-U$_$%@3@#PE((/D]T73$0E+0(W(8P$Z\&S*X08* MACP$-03>YG(/@`?](T?'0T%RB13K-H"?H`+&B!264&#(LXE-)G>?($QT>'5G ME9!*]I8AN9>Q-2[#\1=[X!NW=P<_\0E-H%1$-90%`)0"5QRL@BY,V4'+ADK7 M$67(I!^:$`E1%AW+9G/10561H)K6P9H<,INRYQ0#X@?I>"9ZX!2)4#+BJ"<) M``&"PAI!\0E!MI1-$YW2N9S'(A27N2<%H)G%_G%#GVDR\S(`+YA;0L(328DM MISF=Z$DQ*K86A4!J!U`C$%$(!'"(`C,P]`D?-0`_C6(4Y:F.Z?F?%*-,X[*- M[N,Y05$(`=`UQC",U2$)3[`\ MK7DH=/!7D.=Z$X`!L+>C%T!S+IH4`)"F-(DHLS<9GR`"R.4J+\@4#2%C(OHI M&0H:!J%4,H)\,D50_N&TIM'AAE[UI86"3A<@`5=I%!^U73M::X9Z%`Y`:ZV' M*,IT(BTH0U:#(YZ`"4OZ'J&Q)K/W"7;@B`G@*<`R1$X)`@_@H];!!B=D`;1I M*`#D`1/PJ(<"01^`F,L!3IEZ*'UH,`8!CAR3`/62=F:WIZ7JC:Q!6R):<4Y% MJ'(7"5]@-FA@%&E@!#^P!9JD"6,@5V/E!62`D9]P"61@!$,P!%&`KH:6K4GX M"5_P`_[T"8,@KW:C"8XS!+*:%'V0!>TZ!$>0!6QI%'1`!@IT63T`-P.1!V2` M!FR3%'C`!$(P!$\P8$A!"?):;VTP!$)@!3:'"%]P!!<[!%3`02*D0!)0_JE& M@54?,*P)2P9?(%&-8`47J[+K%P7M:@1;<$;Z\3)%0:$/,@#:^1FJ5C\7`JH^ M)A`+>@`&ZE1.6:AW^#WS1'.%V0`AU&R!368XD4^0`8^07&$XM1 M8#L`8`3T"CR!!CL4,`%8-5&_PPT&L^``.8`&1P%AP65>?]%$/\)5Z"P`.<$8`0*G.(:R)=T_C\P5H8#P( MZ0-)$0@78+IS.SXH<*O6L9X)8Z3K<0#U0B#-JB3PL3_;(AFAIBJJBGNR-D0$ M]:OU%@C3-0(@4*:T=EDSH%BYB*D9X`!N^PD/_E1K4L1YJ[N+8O``"@28%^!8 MSC,&WIL!*C`!4[2P#[!>GS!7M1:D4VN8UEN\F/I5`]&5E0>0F.H`Q89I;`"* M?SL"%'`!"TL!+E!"EWI9L#>UG(<4G6N\S@&SPZIUW\N0T@L`=GF'Z3L!;$5% M!;D?F_IB1H$%P3N^*;*@P93GLNBV0A34EK>`` M1Y0&`V$%4YMI2\!?8U4",U`"]]N#I\A_#T#`%#`";C`'W@4``\&*8X7#.@S$ MSH<)LU,\1X`)GW"X_K0&``>;B\"J'*![%$+0M1=``3(0LPI$`=6KE5X+1GGP M!7/U.PZH'=E($?C3))YR(J(Z8R,Z*"N<$R2S:CP4,<0[R<>+59?E9>B&:?3D M!@Z@0+9Z%#*PHA2PC$9!0;KX"5%LQ0/X%\'\`8Y*8-++.)9`"&9&K\4+`/2D M0,;,J_B;`3_W5!102MY3:RE%QQ]@A$:1!%T;69]D2W#4AFD:3MN:/9[;'`D\ MP2MJ5G9C"83:94;!!S5\74=!!B3P`[\&PB5*&3+CG3NT)BC\3!>RDYO9D[UW M`([@3:XJP_5&PS'[`-.3Q;)\%&E`:+0TM1=``TMP!$R$J1.04MU;T?#:_KV8 MUCM>G*L?FG"!8`6;1U"2!LU'`815@!35G,8T8`$><`$R@!0]_5R>1<=&K$0P M2\Y(00A?T`/A(\W2)D*L_+F8FGB)+,U'\0)NZF5;0*B.^1^R"QL,[2*FUKL$ MD;LQ,LJF:AA&@0"I4:!/P3RL^YS8C)FK;=BFH4<&E$`(":S="YO9)83& MD-J#8644+Q"81NT`;,E^@4PXEF`[8[4%AZ`)4.W:[T!J9](!0)(3F:"G2I(GI4R=BO()2.`;/177R=$_ M=-W*F(;=C`#5-.%3PQ8=C"0$^R:XM MT52-YI]PZ[CLV=A'P&;U:V+F`";WVA9PA-,1IXPA"6XM*;SR%P=]``AP:LIM M'-WR"3O@B.U1`&"P)H,ZU8:6U(N#!^`$`#[^"8OPSE]UE3UPJ68E166*R4:1 MY$E!ZDI.:T8!?Y?U`27P/;FJW0XV5N/C>G!>>MVM/-TMR``\O<-^X)H&_L06 ML.HL&4X0KL_N7-5O;MM93>V:EJ8WK'>7E0%_X:O@7!TA+!HY`09!=C1EG;OF M@>@K6!27P`'!^2`'<%0LC!0KM#Q>4+7+8V9I5#O>QD^MZU9&<00&=+F.2T)& M@;:UHQQDOSQ'`06ZPV"?@`)X_EX2$&E[/&V-B[G.-[C@@Q2!\%5X.SX6T,R- MNSP%KCTA1#S'\SV$)03`<]C94SOON!R:6_8-ICM)E@+`\]^?4(6FF[DOH"': MTP*QFS[&>B\#05M#.0!6LSD;AF8!Z&;O(0%!CHRY,E2[X0HFCP MX$2*(4-ZXO3)TR=.)U.B-,E2Y2<$!Q8D6##3)LT"(2`DH*E(H":3)4FV7"FP MD(D"-)765)J@P!JB*D^*I%K5ZE6L6;5NY=K5ZU>P8<527"FTDU27GX"6_&0) M`<^;3&?RY"EHH%"7>`7ZL5%`YM*X"09`Q5MV[&'$B14O9MPXL:>S>7\2C2I0 M$EVY2YM"0`+GDE4]_F$J#/B;.6Z`-P*'0@[JV/5KV+%ESRZ,MF39ET,O'8!+ M,^[_W1;;:LGU5MMET36WW7#3/3?>=Z6EEUU[R\676WW'G;=?:_]==]P\N=1O MT8*KHT@32!(I1)%")!GI347U1')/%Q$^B;^-IS/12F33&O'CED;66%:2.PX9 MY(M93AGEDTT.6>:+:3;1YAYQWA,_VPX6&=DN=(&:*B0N>]:88I>\0]C(G6-. M:S4XE9[Y:;.J=!HOJ*V>&NNJDS;Z9ZXS]GKGFZD6NVNF.P[;3JSA9$OHL8L& MFC(2]USK9+G1_E)JK/7D&$ZROT92;[7U2YEP6@T_^NR2+<2;.\!+%'SOG!U? +&?+*66SYDX```#L_ ` end GRAPHIC 3 b51065fsb5106501.gif GRAPHIC begin 644 b51065fsb5106501.gif M1TE&.#EAG0!'`/<```!"(0`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`/_6 M"/_6$/_6&/_6(?_6*?_>`/_>"/_>$/_>&/_>(?_>*?_G&/_G(?_G*?_O(=[& M,>;:-??>,?O:-?_>,?_G,?_>.?_G0?_O2O?>4O_>4O?G6O_>8__B:_?G:_SI M__O=_?GA/_KA/_GC/_OC/_GG/_OH-[FO?_OK?_OM?_OO?_WI?_WM?_W MO?_WQL;.SL;6SKW6UL;6UL[6UM;6UKW>SL;>SKW>UL;>UL[>UM;>UM;>WKWG MUL;GUL;GWKWOWL;OWL[GWL[GY\[OWL[OY];GWM[GWM;GY][GY];OWM;OZ];W M[][OY][O[][W[][_]^?OY^?O[^?W[^?W]^?_]^_OY^_O[^_W[^_W]^__]^__ M__?W[_?W]_?W__?_]_?____OSO_WSO_WUO_WWO_WY__W[__W]__W____SO__ MUO__WO__Y___[___]____RP`````G0!'```(_@#_"1Q(L*`[?K+*X&Q8-GLJ7+ES`OWC,TJ57, MFSASEH3G#Y\\084H_6/Y#Y\_G4B3)M6(#Q\_?+`$/1KD:]V]?N[Z*=W*]>6[ M>^_@T1,EB-(@6/_8_6OWL:O;MS+[J8.7BQ"E1XY&U6-YCRC9'JZ'DOI&G+EDV#=&L\3S\D/.C&-6$!TFG0 M*WSJW--8?012A(\H@^`&@@J!B$*/.^N45^"$#\U3EB&:`%*!!5OP\D]8[E`H MXD`?+53+((88L@D6#7"@PX?OR#;B7TT-V,Y0C%G4UUJI%&*(<2Q<@$$(YQ3% MU(RBPW`T,ZS4YD#SRPH,B>%@K\FN^O)4#09;U(D5/``R>```'G*]]\ET\``H`,V)-`/O+*%\#3C`,I+Q,!'T2G<)R,$TUF*S?YQ# M""">0-A"`!">` M0`Z"80TJ+.`$)4``%WH"#R/@+@*I6X;X=.>ND6TP!CDQ!&"J(48+S`@@`A%_KH# M!BYP@@A0,9O/:AD\>)``)B:`"P0A),0@-H[&^&%J/CQ;;]2@R5X]X!J.T4,# MD$DR:1@P!V>,``)4]0XBY"ND4)`5`L;&2'^2``'R.@,<]"`R7_$`&'Z``Q_L M-)F&-,D>A0A*(NY!A7PE8"#C`*.O0D"`.F#N1O`(D1@2X*YF0J`.3`0Y&(@Z%O``)2Y`";XKBKFZU!I= M2,(LMR#'`D2P@$,.A`H;G15FV>*TGHX!6>Y"_E4:%H:/=$#2!$-:`!QT1@X7 MP/$!08`92X"0.])Z,*QG/.JJ_M'6?"V`)7C(EPE(U@8A!F-63#W&/ZQ0Q.F& MD0I$@4<,0@`"9#:`!N'HS3DHFT6[&J4I4"W(/3JS"DD8(A7_F`,YZ6#`?^@! M`1#3)`'*X4XA_N.U:(28->;[)"XT8%$;K)-`V$"`@S6`?H3YRC_84"IW)<`, MWZCP&Q\0`VW^@P<]I*)VH9!.$1`@B"P9QP2:N$&$6@%?&VR`.(K2F#T0P(K^ M#$$P!'*.?"T5"HZQCG(*\A5WU$,1A%C$+O[Q!)9VPTC60<`&1Y8`+K4C1)0" MPU8W.(36W(U?;MCH_K4FT#D?+-*@?#@:2_!QA[&=0%Q+>.AC&W`$G;%D"9H, M`14+:&0F`H!TO7$!=ID@SQ[FZPFK:DTW;+!!W(:`#T,9AZ_$E0#W0O5J!?%' M6'(Q"$B\`A[L0$&IA#"4UCR+"85L`&8;TZE_B#E9"9A"TVZDC-2>D0#:^$X(+S/$,##$I'!'@U']\:Y&IL^MF"[*I5*!(+75H@(NK^][>I.&O!X.`1Z'* M$C8`^%<-2$-O&A.B<23`F2(8``GU,-I2B<`&.U[;,URYP2:J@0&_[;,0_A79 M\00$@P[(&M(#<,`0(^@[7RH0!Q=P%\<&W($A2WBE"!#`1DV[,'59Z)=#"'./ M040B%^OX1Q5D=8)G8*Y3QF!B"`DPVQRQ9)QH1`!_Y_RA-@;6K6[XAU;CN$$? M].YFVXB!Q7U8!U2.C,0&CD%%7?R.-+P\L"Y(AC*.,8QD+,/E9\S2.;+088D- MN2!/>&4(V"V0;HQ6C@G(IIT@TI=;""(YHJX`/95@!"0$@0A',,(1\"6Q$,A@ M7K:*`VR9BFD976W,J%+5%V2%Q0<0@5[X2/M)1=H'&RRR5`@HB"87V8`;_.,+ MR$I=ZM!WOO-I<@$@@-@Y;DSL!)02\2+;>;N'_O%79$;>P`Y1B"D*L9)_[.'9 M1@ZC^GT56!&(\`&'=UI^BV@J!#"#,%!MS-1.8(*1_F,*^F911`!J`X$-KI0O M5-0'9-``(L140]8;Z#``.I0`LU58S71&&?!S$1!;NO,`&B`.H"0"'A9_`Y%X M$%-M`C$,+Y/0/N@=8&-``>7`.*+!!XD(%"W,&]%=9-]($V!5N MUR`-T\`,TG"&9FB&SP`/;(56)"@0)F@P?B`0QT!9:B1Y-500\$`+@^`8XU`# M^E(&9J`_A)@&@E@#_O2T@1K`$D0A!P#'5'#5)!:S5=.5`-556"(3`D&`)P(A M#:[T?@G@5'I0`&\T1V#0#G-`;()E#`*1!5CB72M0%+W1%`8TB]MU4F'TAE3V M2ODRA\>S57/4@A!Q(+H05?^`!V>5`/3#$)]!?8PT1R1$%$&(+PB`:4/A)>F@ M91S55,=71/UD>Y%"$,CP6/1DCT45MV5"M3CTK2 M)-LU8G.DBW&X0=98AU75`-DD00TA#ZQ`'O]P!=6$#$8BB4K2&"CG0G'T`$'' M$__@B%FW=`('((L\5A1CPA)M>$W\R(L/8(V]ECO?ER,/80OQ$"'/.#(W<&P$09:.Q4!)UQA? M4``(<'/GX(+6L0XW\@P`T("+IUT:P75'02E6L``EQX\+8`+OYXM\,#8>9D<[ M\EX?HB0ILQL+\Y47T`!!EQ$"<0/+!GP%M!!V@`"QI5<"T1?\0D3/^``R`+24$-GT%P/$`6CF08'X"L"\9=[\C=]05D;=`($("_6\64Q@X]*ITF- MI%W8)RX;Y(MU<#"HDDTQ,RAV\@Y-<@_[0!GV_O`/A`2*+P-!A\;8S-@-?O3$9C/$.&2A* M751"+,$'1D9/!#`.=J)?'29*?]`E?/(-'(4O!=08MJ0[(E``=E00"J!.(4`# M.9(%"%`"5(1N)>0/-Z('R5OP5I`Q$&6S4R M)\`D^/`-:F3E.R,0K)+X#W8``-="`'M0.F#(2`A0-04V`UNF MI;)"/L[W`JK2&)^Y5+]"`3`114DV42P_@B_\0HA&` M`9M*$%Q`A!!0!/_0>:/Y#8#X*WKPA`.1J1O&7B^$`-I"!UH66T8P`=E38;^B M`ABP19.W7'[E0@^0`7KP#NKPEM>4`^$@1"PF@@;C1&>4.DS%!#(2!ZCT_G-S M5$3C\P`($'3W8%(8<&VX@TY`(RH4@`8``]=(`WG``6)J0R0QA)> ML`-08`2LYH(DZD5"4`--0`5/T`0^P`3MH)6H"U4$`,Z)"T,?`.@\JV M:T-YUXF9TV@J#7`V^FD&4R`%9G`YM>4DE#(HJMH&66`%5/`%;#0WM"40X_`# ME=4$46`%36`$BQ=8#R`N$>!T2(D-<<`%4F`%7&`'S+(G2$HO#7H2)]$3ZD`S MIJ,&5C`%7A`'?%&QYL(7H4H1!,DG+#$'I+B80C<0FS(0?F'$#Z%D?&)^,8`` M3)!QN=D-9'!6O6(""\!&,M%?0A/``\(VHUE"-],I'1H3MC('SWM-=L02!&D2 M#9H,%9;"#N%72C1'_G/`,!#!)':**G7<7RYAQ&K7`$U@).M:%%TXQH+\$"Q1 MDZ@3K'8<$RRQGW,D44QV(^/E7'^0AY/L&/PB9G"$R8CL$C<"!P6`6!C&9+TQ M`Z^T`-50R@UA2?\P5?BBRC&!CS=&1;-U=M?X01G+;*N,RT.Q*0CFQ%SW$G7C MBB)$LP;1&*18*ME$RI-,.F#05A?@RS"Q*6W05CA`S#J#!P\G:-B@S(AD*V!@ M9*;H&'=,$@N!#^,``&^DHPTQ#CT@:`107<;)SM?($B%X39*7S#O1#D